From the pharmacy bench to
a modern product company.
The pharmacy on Bridge Street opened in 1949. Michael McLoughlin grew up above it. He went on to spend fifty years as a pharmacist and master compounder, building an independent pharmacy chain and preparing formulations by hand for people he knew by name.
Working with the same ingredients across decades, he saw a relationship between them that nobody had developed into a protected commercial formulation. Epitheal developed it: a highly novel, non-steroidal, antibiotic-free wound-care formulation, protected by a granted US patent.
The timing was not an accident. Antimicrobial resistance is pushing clinicians and patients toward alternatives to antibiotic-based approaches, and the long-term effects of repeated steroid use have made the same category scramble for alternatives.
Demand is moving toward exactly the kind of formulation fifty years of hands-on compounding pointed toward.
We are building a portfolio around it: skin recovery, advanced wound care, and regulated medicines for human and veterinary use. That's where the Epitheal story, and the future of skin recovery, begins.
Meet the team
